An Immunogenomic Investigation of Oral Cavity Squamous Cell Carcinoma in Patients Aged 45Years and Younger

Objectives/HypothesisTo investigate differences in the immunogenomic landscape among young patients presenting with oral cavity squamous cell carcinoma (OCSCC).Study DesignRetrospective database review.MethodsNormalized messenger mRNA expression data were downloaded from The Cancer Genome Atlas (TCG...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Laryngoscope 2021-02, Vol.131 (2), p.304-311
Hauptverfasser: Maroun, Christopher A, Zhu, Gangcai, Fakhry, Carole, Gourin, Christine G, Seiwert, Tanguy Y, Vosler, Peter S, Tan, Marietta, Koch, Wayne, Eisele, David W, Pardoll, Drew M, Mandal, Rajarsi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objectives/HypothesisTo investigate differences in the immunogenomic landscape among young patients presenting with oral cavity squamous cell carcinoma (OCSCC).Study DesignRetrospective database review.MethodsNormalized messenger mRNA expression data were downloaded from The Cancer Genome Atlas (TCGA) database. OCSCC patients were categorized into young and older age groups with a cutoff of 45 years. Human papillomavirus–positive tumors were excluded. Cell fractions, marker expression, and mutational load were compared between age groups using the Wilcoxon rank sum test. Adjustment for multiple comparisons was performed using the Benjamini‐Hochberg method, with a false discovery rate of 0.05.ResultsTwo hundred forty‐five OCSCC tumors were included; 21 (8.6%) were young (37.1 ± 7.5 years) and 224 (91.4%) were older (64.5 ± 10.3 years). There was no significant difference between groups in the fraction of B and T lymphocytes, macrophages, monocytes, natural killers, and dendritic cells. Cytolytic activity score was decreased in young patients (8.33 vs. 18.9, P = .023). Additionally, young patients had significantly lower expression of immunomodulatory markers of immune activation, including PD‐1 (PDCD1, P = .003), CTLA4 (P = .025), TIGIT (P = .002), GITR (TNFRSF18, P = .005), OX40 (TNFRSF4, P = .009), LAG‐3 (P 
ISSN:0023-852X
1531-4995
DOI:10.1002/lary.28674